Hero B - Search Results

1

Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.

Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Hero B, Eggert A, Berthold F, Fischer M. Ackermann S, et al. Among authors: hero b. Clin Cancer Res. 2011 Feb 15;17(4):731-41. doi: 10.1158/1078-0432.CCR-10-1129. Epub 2010 Dec 17. Clin Cancer Res. 2011. PMID: 21169242

2

[Neuroblastoma: diagnosis and therapy].

Wargalla-Plate U, Hero B, Berthold F. Wargalla-Plate U, et al. Among authors: hero b. Praxis (Bern 1994). 1995 Oct 10;84(41):1152-7. Praxis (Bern 1994). 1995. PMID: 7481325 German.

3

Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma.

Christiansen H, Sahin K, Berthold F, Hero B, Terpe HJ, Lampert F. Christiansen H, et al. Among authors: hero b. Eur J Cancer. 1995;31A(4):541-4. doi: 10.1016/0959-8049(95)00030-m. Eur J Cancer. 1995. PMID: 7576963

4

The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients.

Berthold F, Hero B, Breu H, Christiansen H, Erttmann R, Gnekow A, Herrmann F, Klingebiel T, Lampert F, Müller-Weihrich S, Weinel P. Berthold F, et al. Among authors: hero b. Ann Oncol. 1996 Feb;7(2):183-7. doi: 10.1093/oxfordjournals.annonc.a010547. Ann Oncol. 1996. PMID: 8777176 Free article.

5

[Hepatopathy in patients with stage 4S neuroblastoma].

Claviez A, Hero B, Schneppenheim R, Berthold F. Claviez A, et al. Among authors: hero b. Klin Padiatr. 1996 Jul-Aug;208(4):221-8. doi: 10.1055/s-2008-1046477. Klin Padiatr. 1996. PMID: 8926687 German.

6

Prognostic significance of the proliferative activity in neuroblastoma.

Rudolph P, Lappe T, Hero B, Berthold F, Parwaresch R, Harms D, Schmidt D. Rudolph P, et al. Among authors: hero b. Am J Pathol. 1997 Jan;150(1):133-45. Am J Pathol. 1997. PMID: 9006330 Free PMC article.

7

[Risk and benefits of surgical interventions in localized neuroblastoma--experiences from cooperative studies in Germany].

Hero B, Holschneider AM, Berthold F. Hero B, et al. Langenbecks Arch Chir Suppl Kongressbd. 1996;113:1062-9. Langenbecks Arch Chir Suppl Kongressbd. 1996. PMID: 9101782 German.

8

Does megatherapy contribute to survival in metastatic neuroblastoma? A retrospective analysis. German Cooperative Neuroblastoma Study Group.

Hero B, Kremens B, Klingebiel T, Bender-Götze C, Burdach S, Schrappe M, Berthold F. Hero B, et al. Klin Padiatr. 1997 Jul-Aug;209(4):196-200. doi: 10.1055/s-2008-1043950. Klin Padiatr. 1997. PMID: 9293450

9

The current contribution of molecular factors to risk estimation in neuroblastoma patients.

Berthold F, Sahin K, Hero B, Christiansen H, Gehring M, Harms D, Horz S, Lampert F, Schwab M, Terpe J. Berthold F, et al. Among authors: hero b. Eur J Cancer. 1997 Oct;33(12):2092-7. doi: 10.1016/s0959-8049(97)00237-2. Eur J Cancer. 1997. PMID: 9516860

10

10 years' neuroblastoma screening in Europe: preliminary results of a clinical and biological review from the Study Group for Evaluation of Neuroblastoma Screening in Europe (SENSE).

Erttmann R, Tafese T, Berthold F, Kerbl R, Mann J, Parker L, Schilling F, Ambros P, Christiansen H, Favrot M, Kabisch H, Hero B, Philip T. Erttmann R, et al. Among authors: hero b. Eur J Cancer. 1998 Aug;34(9):1391-7. doi: 10.1016/s0959-8049(98)00135-x. Eur J Cancer. 1998. PMID: 9849422

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

192 results

Search Page

Filters